Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Infliximab treatment for pediatric refractory Kawasaki disease.

× No keyword cloud information.

34 in total

1. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors: M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal: Arch Dis Child Date: 2004-08 Impact factor: 3.791

2. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.

Authors: Hiromi Muta; Masahiro Ishii; Jun Furui; Yosikazu Nakamura; Toyojiro Matsuishi
Journal: Acta Paediatr Date: 2006-02 Impact factor: 2.299

3. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors: Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal: J Pediatr Date: 2006-08 Impact factor: 4.406

4. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors: T Kawasaki
Journal: Arerugi Date: 1967-03

5. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors: Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245

2. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.

Authors: Yun Ju Lim; Jo Won Jung
Journal: Yonsei Med J Date: 2014-09 Impact factor: 2.759

Review 3. Recent understanding on diagnosis and management of central nervous system vasculitis in children.

Authors: Ludovico Iannetti; Roberta Zito; Simone Bruschi; Laura Papetti; Fiorenza Ulgiati; Francesco Nicita; Francesca Del Balzo; Alberto Spalice
Journal: Clin Dev Immunol Date: 2012-09-12

4. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.

Authors: Chun-Ling Han; Suo-Lin Zhao
Journal: Med Sci Monit Date: 2018-10-11

4 in total

Infliximab treatment for pediatric refractory Kawasaki disease.

1. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

2. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.

3. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

4. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

5. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

6. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

7. Infliximab as a novel therapy for refractory Kawasaki disease.

8. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

9. Kawasaki disease in the older child.

Review 10. [Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease].

1. Seasonality of Kawasaki disease: a global perspective.

2. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.

Review 3. Recent understanding on diagnosis and management of central nervous system vasculitis in children.

4. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.